35 results about "Hematopoietic precursor cell" patented technology

The invention generally regards methods for providing ematopoietic cells and precursors of hematopoietic cells from a variety of cell sources, such as pluripotent stem cells or somatic cells. Also provided are therapeutic compositions including the provided hematopoietic cells and precursors of hematopoietic cells, and methods of using such for the treatment of subjects.

The present invention relates to pluripotent stem cells and methods of promoting long term growth of such cells. In particular, the methods described are used to enhance the proliferation of hematopoietic stem cells, hematopoietic precursor cells, hemangioblasts and endothelial stem cells. The present invention also relates to methods of using such cells, comprising introducing such stem cells, into the host. The present invention also relates to pharmaceutical compositions comprising the cells and such compositions may include growth factors or cytokines to allow for further cell growth and/or cellular differentiation. The invention further relates to methods of in vivo administration of a protein or gene of interest comprising transfecting the stem cells grown by the methods described, with a construct comprising DNA which encodes a protein of interest and then introducing the stem cell into the host where the protein or gene of interest is expressed.

The invention relates to the field of stem cell biology, and discloses a preparation method of natural killer cells differentiated from human pluripotent stem cells. The preparation method comprises the steps of S1, forming an embryoid body; S2, performing directional permanent hematopoiesis differentiation on the embryoid body to obtain hematopoietic precursor cells; and S3, differentiating the hematopoietic precursor cells to obtain natural killer cells. The invention also discloses application of the natural killer cell prepared by the method as a pharmaceutical composition for preventing and/or treating tumors by cells. According to the method, efficient and stable differentiation of the NK cells is achieved, EB adherent differentiation is achieved in the induced differentiation period, TGFB inhibitor treatment is prolonged, 10% or above of CD34+CD45+permanent hematopoietic HPCs can be obtained through rapid induction. The method has the advantages of being efficient, stable, low in cost and suitable for large-scale cell preparation production; and the method is easy and convenient to operate, the NK cells obtained through differentiation have typical NK cell surface marking molecules, the anti-tumor function of the NK cells is superior to that of the NK cells derived from umbilical cord blood, and great scientific research and clinical application potentials are achieved.

Provided herein are methods for the efficient in vitro differentiation of HLA homozygous blood cell-derived pluripotent stem cells to hematopoietic precursor cells, and the further differentiation of the hematopoietic precursor cells into HLA homozygous immune cells of various myeloid or lymphoid lineages, particularly T cells, NK cells, and dendritic cells. The pluripotent cells may be maintained and differentiated under defined conditions; thus, the use of mouse feeder cells or serum is not required in certain embodiments for the differentiation of the hematopoietic precursor cells.

Immortalized human stromal cell lines sustain and expand human hematopoietic precursor cells. The precursor cells are obtained from a blood product and inoculated into a culture medium conditioned by exposure to a human stromal cell line. Preferred human stromal cell lines secrete SCF, LIF, MIP1α, and IL-6, as exemplified by a human stromal cell line designated HS-1. The conditioned culture medium may be supplemented with additional growth factors, such as interleukin-3. After expansion the human hematopoietic precursor cells are harvested and returned to a patient or frozen and stored. The immortalized human stromal cell lines can also be used as feeder layers in ex vivo bone marrow cultures or in colony forming assays.

The current disclosure describes methods of expanding precursor cells for hematopoietic transplantation in subjects. The methods culture precursor cells in media containing an immobilized high molecular weight LILRB2 agonist or an LILRB2 agonist in combination with a Notch agonist. The expanded cells can be used to treat a variety of hematopoietic disorders.

The invention discloses a method for preparing CD19-targeted chimeric antigen receptor NK cells from human pluripotent stem cells and application of the CD19-targeted chimeric antigen receptor NK cells. Specifically, the invention discloses the method for preparing CD19-CAR-NK cells, which comprises the following steps: directionally knocking a CD19-CAR gene and an EF1 alpha promoter into a human pluripotent stem cell genome AAVS1 region by utilizing a CRISPR/CAS9 system of a targeted AAVS1 site to obtain recombinant human pluripotent stem cells (CD19-CAR-hPSC), then inducing and culturing the CD19-CAR-hPSC to differentiate into embryoid bodies, sorting CD34+ hematopoietic precursor cells from hematopoietic precursor cells differentiated from the embryoid bodies, then directionally differentiating to the NK cells, and finally differentiating into the CD19-CAR-NK cells. The CD19-CAR-NK cells disclosed by the invention has higher multiplication capacity, higher purity and stronger anti-tumor capacity, and can be safely and effectively used for tumor immunotherapy.

The invention provides application of CD61 as a hematopoietic endothelial cell marker as well as a kit and a method for detecting hematopoietic endothelial cells. The kit comprises a reagent for specifically recognizing the CD61. In a hematopoietic differentiation process, the endothelial cells of CD61<+> have potency of generating hematopoietic precursor cells, namely the endothelial cells of the CD61<+> are hematopoietic endothelial cells. The kit and the method, for detecting the hematopoietic endothelial cells, provided by the invention have the effect of detecting the hematopoietic endothelial cells in the endothelial cells in the hematopoietic differentiation process quickly, sensitively and accurately.

Methods of differentiation of pluripotent stem cells into hematopoietic precursor cells, wherein the method is carried out under suspension agitation, and wherein a GSK-3-inhibitor or a Wnt pathway activator is added during a stage of mesoderm induction, and cell culture media for use in the methods, as well as kits for performing the same.

A method for detection of a precursor T cell or precursor B cell, a method for evaluation of the property of a hematopoietic precursor cell in a source for transplantation, and a kit for use in the evaluation are disclosed. A precursor T cell or precursor B cell can be detected by co-cultivating a stromal cell line with a monocyte. By using the detection method, a precursor T cell or precursor B cell can be quantified and can also evaluate the property of a hematopoietic precursor cell in a source for transplantation.

The present invention provides novel use of the MK family that is used alone as an agent for proliferating hematopoietic stem cells and hematopoietic precursor cells. The invention also provides an agent for remarkably enhancing the above-described effect for promoting the proliferation of hematopoietic stem cells and hematopoietic precursor cells, comprising the MK family in combination with known hematopoietic factors such as IL-3, IL-6, G-CSF, GM-CSF, M-CSF, SCF, and EPO.

The invention provides a tumor vaccine and a preparation method thereof. The tumor vaccine comprises dendritic cells which block signal pathways of CD44 and CD11b molecules. The invention further provides a method for preparing the tumor vaccine. The method includes the following steps: (1) acquiring mononuclear cells from peripheral blood or umbilical cord blood of a mammal, inducing the mononuclear cells into mature dendritic cells or acquiring bone marrow hematopoietic precursor cells from bone marrow of the mammal, and inducing the mononuclear cells into mature dendritic cells; (2) blocking the signal pathways of the CD44 and CD11b molecules of the mature dendritic cells; and (3) collecting the dendritic cells blocking the signal pathways of the CD44 and CD11b molecules. The tumor vaccine has a good anti-tumor effect, a wide anti-tumor spectrum and good use safety.